Reviews/Epilepsy Management/Fenfluramine in Dravet syndrome
Novel Mechanisms · EP-NOV-01 · v2
Fenfluramine was tested against a dummy pill in three separate blinded trials of children and young people with Dravet syndrome, and in every trial the drug cut the number of convulsive seizures far more than placebo [1][2][6]. When the results of all three trials were combined, the benefit held up across different ages, genetic subtypes and numbers of prior medicines tried [22]. Doctors treating patients outside of trials, in several countries, saw the same kind of large seizure reductions [7][8]. The outcome the studies measured, fewer convulsive seizures, is exactly what the claim states. The main cautions are that the pivotal trials shared a sponsor and a recurring group of investigators, and that some of the supporting papers re-analyse the same trials or rely on seizure diaries kept by caregivers.
Three independent double-blind placebo-controlled phase 3 RCTs each met their primary monthly convulsive seizure frequency endpoint: a 62.3% greater reduction versus placebo at 0.7 mg/kg/day in [1] (N=119), a 54.0% greater reduction in stiripentol-treated patients in [2] (N=87), and a 64.8% greater reduction in [6] (N=143). A pooled post-hoc analysis of all three trials (348 patients) found greater seizure reduction with fenfluramine than placebo across age, prior-ASM-count and SCN1A strata [22]. Real-world cohorts reproduce the signal, with 68% of patients reaching a ≥50% reduction in total seizures and 67% for generalised tonic-clonic seizures in Germany [7], and ≥75% reductions sustained across age groups in the European access programme [8]. The measured endpoint is identical to the claimed outcome. The contested point: The division is not about direction or size of effect, which is consistent across every source, but about how much independent corroboration the corpus truly holds. The Sceptic notes the pivotal trials were Zogenix-funded with overlapping authors, that [18] reports the same stiripentol trial as [2] and that [9], [16] and [22] re-analyse the same three RCTs, so the independent datasets are roughly three trials plus the real-world cohorts rather than the full paper count.
All 22 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Epilepsy Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal trials were Zogenix-funded with a recurring author set (Sullivan, Lagae, Nabbout), introducing sponsorship and investigator-independence risk, though this does not alter the direction of a blinded, placebo-controlled primary endpoint.
Apparent breadth is inflated by overlap: [18] reports the same stiripentol trial as [2] (N=87), and [9], [16] and [22] re-analyse the same three RCTs, so the independent datasets number ~3 trials plus the real-world cohorts, not the full count of papers.
Where it remains uncertain. Apparent breadth overstates independence: the pivotal trials shared sponsor and authors, and several papers [9][16][22] re-analyse the same three RCTs while real-world data are open-label [7][8].
Aleatory
Not all patients respond: responder rates of 54% in [2] and 72.9% in [6] mean a substantial minority do not reach a clinically meaningful reduction.
Epistemic
Several papers [9][16][22] re-analyse the same three trials and [18] duplicates [2], so independent datasets number ~3 trials plus real-world cohorts, fewer than the paper count suggests.
Inferential
Real-world efficacy [7][8][11][12][19][20] and the trial endpoints rely on caregiver-recorded seizure counts, which are open to expectation and reporting bias in uncontrolled settings.
The load-bearing papers from a corpus of 22, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal non-stiripentol RCT meets primary convulsive-seizure endpoint
“The study met its primary efficacy endpoint, with fenfluramine 0·7 mg/kg per day showing a 62·3% greater reduction in mean MCSF compared with placebo (95% CI 47·7-72·8, p<0·0001)”
Panel auditInternal validity: high · scope of inference: Children and young adults with Dravet syndrome not on stiripentol, 14-week adjunctive treatment.Key limitations: industry funded · short duration · add-on design
Independent RCT in stiripentol-background DS patients confirms effect
“Patients treated with fenfluramine achieved a 54.0% (95% CI, 35.6%-67.2%; P < .001) greater reduction in mean monthly convulsive seizure frequency than those receiving the placebo.”
Panel auditInternal validity: high · scope of inference: Children aged 2-18 with Dravet syndrome on stable stiripentol-inclusive regimens.Key limitations: background stiripentol only · short maintenance period · industry context
Third phase 3 RCT replicates magnitude of convulsive-seizure reduction
“Patients treated with fenfluramine .7 mg/kg/day demonstrated a 64.8% (95% confidence interval = 51.8%-74.2%) greater reduction in MCSF compared with placebo (p < .0001).”
Panel auditInternal validity: high · scope of inference: Patients aged 2-18 with Dravet syndrome not receiving stiripentol.Key limitations: short duration · add-on design · industry context
Majorities in each age group achieved ≥75% reduction in monthly convulsive seizure frequency, pointing toward reduction, though against pretreatment baseline only.
Panel auditInternal validity: medium · scope of inference: Dravet syndrome patients across <6, 6-17, and ≥18 year age groups in the EU early-access program.Key limitations: no control · physician-chosen dosing · no significance testing reported
4 of 22 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent high-quality RCTs on the exact population and outcome, corroborated by real-world data, carry the claim to the Established tier despite sponsorship overlap.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Sponsor-independent confirmation. The pivotal RCTs [1][2][6] were Zogenix-funded with overlapping investigators, leaving effect-size confirmation reliant on a single sponsor and author group. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An investigator-initiated, independently funded randomised controlled trial of fenfluramine for convulsive seizures in Dravet syndrome.
Open question: Does fenfluramine's reduction in convulsive seizures translate into reduced SUDEP or mortality in Dravet syndrome? Why it is still open: Every included study measures seizure frequency; none reports SUDEP or mortality as an outcome.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19